Literature DB >> 20180858

Towards a Brucella vaccine for humans.

Stuart D Perkins1, Sophie J Smither, Helen S Atkins.   

Abstract

There is currently no licensed vaccine for brucellosis in humans. Available animal vaccines may cause disease and are considered unsuitable for use in humans. However, the causative pathogen, Brucella, is among the most common causes of laboratory-acquired infections and is a Center for Disease Control category B select agent. Thus, human vaccines for brucellosis are required. This review highlights the considerations that are needed in the journey to develop a human vaccine, including animal models, and includes an assessment of the current status of novel vaccine candidates.
© 2010 contains British Crown copyright 2010/DSTL. Published with the permission of the Controller of Her Majesty's Stationery Office. Journal compilation © 2010 Federation of European Microbiological Societies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20180858     DOI： 10.1111/j.1574-6976.2010.00211.x

Source DB:  PubMed          Journal:  FEMS Microbiol Rev        ISSN： 0168-6445            Impact factor:   16.408


  53 in total

1.  Extended safety and efficacy studies of the attenuated Brucella vaccine candidates 16 M(Delta)vjbR and S19(Delta)vjbR in the immunocompromised IRF-1-/- mouse model.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; Y Fan; M M Kahl-McDonagh; T A Ficht
Journal:  Clin Vaccine Immunol       Date:  2011-12-14

2.  Pluronic P85 enhances the efficacy of outer membrane vesicles as a subunit vaccine against Brucella melitensis challenge in mice.

Authors:  Neeta Jain-Gupta; Araceli Contreras-Rodriguez; Ramesh Vemulapalli; Sharon G Witonsky; Stephen M Boyle; Nammalwar Sriranganathan
Journal:  FEMS Immunol Med Microbiol       Date:  2012-12

3.  Hepatic and splenic immune response during acute vs. chronic Brucella melitensis infection using in situ microscopy.

Authors:  Juliane Daggett; Alexandra Rogers; Jerome Harms; Gary A Splitter; Marina Durward-Diioia
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 2.268

4.  Survey of Omp19 immunogenicity against Brucella abortus and Brucella melitensis: influence of nanoparticulation versus traditional immunization.

Authors:  Morteza Abkar; Abbas Sahebghadam Lotfi; Jafar Amani; Khadijeh Eskandari; Mehdi Fasihi Ramandi; Jafar Salimian; Gholamreza Nikbakht Brujeni; Saeed Alamian; Mehdi Kamali; Hamid Koushki
Journal:  Vet Res Commun       Date:  2015-09-22       Impact factor: 2.459

5.  Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.

Authors:  A M Arenas-Gamboa; A C Rice-Ficht; M M Kahl-McDonagh; T A Ficht
Journal:  Infect Immun       Date:  2011-06-27       Impact factor: 3.441

6.  Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.

Authors:  Beata Clapp; Jerod A Skyberg; Xinghong Yang; Theresa Thornburg; Nancy Walters; David W Pascual
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

7.  Importance of Lipopolysaccharide and Cyclic β-1,2-Glucans in Brucella-Mammalian Infections.

Authors:  Andreas F Haag; Kamila K Myka; Markus F F Arnold; Paola Caro-Hernández; Gail P Ferguson
Journal:  Int J Microbiol       Date:  2010-12-01

8.  Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice.

Authors:  Marie-Alice Vitry; Carl De Trez; Stanislas Goriely; Laure Dumoutier; Shizuo Akira; Bernhard Ryffel; Yves Carlier; Jean-Jacques Letesson; Eric Muraille
Journal:  Infect Immun       Date:  2012-09-24       Impact factor: 3.441

Review 9.  Brucellosis in low-income and middle-income countries.

Authors:  Matthew P Rubach; Jo E B Halliday; Sarah Cleaveland; John A Crump
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

Review 10.  Particulate delivery systems for vaccination against bioterrorism agents and emerging infectious pathogens.

Authors:  Yuchen Fan; James J Moon
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.